CERELA   05438
CENTRO DE REFERENCIA PARA LACTOBACILOS
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Prevention of murine TNBS-induced colitis by oral administration of riboflavin producing lactic acid bacteria.
Autor/es:
G. SAVOY DE GIORI; R. LEVIT; J.G. LEBLANC; A. DE MORENO DE LEBLANC
Lugar:
San Miguel de Tucuman
Reunión:
Simposio; V Simposio Internacional de Bacterias Lácticas; 2016
Institución organizadora:
CERELA
Resumen:
Inflammatory bowel diseases (IBD), which include Crohn?s disease (CD) and ulcerative colitis (UC), are characterized by chronic inflammation of the gastrointestinal tract. Even though the exact etiology of these diseases remains unknown, reactive oxygen species (ROS) have been directly involved in their pathogenesis. Probiotic microorganisms have been proposed as an alternative for IBD patients due to their numerous beneficial effects including but not limited to the modulation of the immune system and of the gastrointestinal microbiota. Among probiotics, certain strains of LAB have also been shown to have the capacity to produce antioxidant vitamins such as riboflavin. The aim of this study was to compare the effect of different riboflavin producing strains in a murine model of colitis. For this purpose forty-two mice were inoculated with TNBS to induce intestinal inflammation and three control mice were inoculated with ethanol. Mice were randomly divided into seven groups and orally administered daily with saline solution (mock and TNBS group), individual probiotic suspension of riboflavin-producing strains (Lactobacillus plantarum CRL 2130, Lactobacillus paracasei CRL 76, Lactobacillus bulgaricus CRL 871, Streptococcus thermophilus CRL 803) or commercial riboflavin. One day after the last administration, mice were euthanized. Large intestines were removed to evaluate the extent of colonic damage and inflammation at macroscopic and histological levels. The liver was aseptically removed to determine microbial translocation toward extra-gut organs to evaluate intestinal integrity. Intestinal fluids were collected from the large intestines and the cytokines content was determined by cytometric bead array. Animals that received either one of the four riboflavin producing strains showed lower damage scores (macroscopic and histologic) in their large intestines and lower microbial translocation to liver compared with TNBS group. Furthermore, a significant decrease was observed in the levels of pro-inflammatory cytokines in the intestinal contents of all the bacterially administered groups (except for CRL 76). The administration of pure riboflavin (administered at the same concentration as those produce by the vitamin-producing strains) showed similar beneficial effects. In conclusion, our results show that oral administration of riboflavin producing strains can prevent TNBS-induced colitis in a mouse model similar to the use of the commercial vitamin and these LAB may serve as an alternative or as complementary treatment for inflammatory diseases such as IBD.